Figure 1, Supplement 1

1. 3000 2500 2000 1500 Intensity Units x 10-3 1000 500 0 0.4 2 10 50 200 nM 0.4 2 10 50 0.4 2 10 50 DMSO Oxotremorine (mmol/L) Acetylcholine (mmol/L) Insulin Muscarine (mmol/L) Figure 1, Supplement 1 Figure 1. In contrast to their gene effects, muscarinic agonists (muscarine, oxotremorine, and acetylcholine) did not alter the proliferation of SH-SY5Y cells. Cells were plated at 50,000/well and were exposed to muscarinic agonists, vehicle or insulin for 24 hours. Increase in cell number was measured by Alamar blue assay.

2. INACTIVE COMPOUND NAME Pharmacological Class INACTIVE COMPOUND NAME Pharmacological Class R-(+)-8-Hydroxy-DPAT 5HT1A agonist Risperidone D2/5HT2A antagonist ( + )-7-Hydroxy-2-(DI-n-Propyl- 5HT1A agonist S-(+)-PD 128,907 D2/D3 agonist Amino)Tetralin 5HT1A agonist + 5HT2A Trazodone PD 168,077 Maleate D4 Agnoist antagonist NAN-190 5HT1A antagonist Bupropion DA uptake site antagonist S-(-)-UH-301 5-HT1A antagonist Nomifensine DA uptake site antagonist (+)-DOI 5HT2A agonist 5,5-Diphenlyhydantoin Dilantin; antiepileptic 3-Methyl-GABA (2:1 salt with Quipazine 5HT2A agonist GABA agonist naphthalene-1,5-disulfonic acid) Ketanserin 5HT2A antagonist Gabapentin GABA agonist Agonist at 14 serotonin 5-Hydroxytryptamine (serotonin) Muscimol GABA agonist receptors Clonidine alpha 2 agonist Corticosterone Glucocorticoid agonist Ethosuximide Antiepileptic Dexamethasone-Water Soluble Glucocorticoid agonist Felbamate Antiepileptic 1-(m-Chlorophenly)-Piperazine Glutamate antagonist Vigabatrin Antiepileptic L-Glutamine Glutamate precursor Phenelzine Antihistamine Riluzole Hydrochloride Glutamate uptake blocker Glycine transporter substrate; Imidazole Antiinflammatory Glycine glycine receptor agonist L-Ascorbic Acid Antioxidant Histamine H1/H2/H3 agonist Pindolol Beta antagonist Cimetidine H2 antagonist Forskolin cAMP stimulator Iproniazid MAO inhibitor ( + )-SKF-38393 D1 agonist Carbamazepine Mood stabilizer Apomorphine HCl hemihydrate, R(-) D1/D2 agonist Lamotrigine Mood stabilizer (+)-Butaclamol Hydrochloride D2 antag Lithium Chloride Mood stabilizer Chlorpromazine D2 antag and H1 antag Desipramine NE reuptake antagonist Fluphenazine D2 antag and H1 antag (-)-Nicotine Nicotinic agonist Thioridazine D2 antag and H1 antag NMDA NMDA agonist (-)-Sulpiride D2 antagonist Kynurenic Acid NMDA antagonist Haloperidol D2 antagonist Clozapine Non-specific antipsychotic sites Pimozide D2 antagonist (-)-Butaclamol Hydrochloride Non-specific, non-D2 S(-) Raclorpride (+)-tartrate salt D2 antagonist Buspirone partial 5HT1A agonist Spiperone D2 antagonist Imipramine SNRI Thiothixene D2 antagonist Clomipramine SSRI Pimozide D2 antagonist Fluoxetine Hydrochloride SSRI Sulpiride D2 antagonist Progesterone Steroid Table 1, Supplement 1 Table 1. Pharmacological profiles of 63 inactive compounds. None of these altered MPHTSSM gene expression in the SH-SY5Y cells, and are representative of the mostly inactive, 1,940 unique compounds tested. Abbreviations: 5-HT, serotonin; cAMP, cyclic adenosine monophosphate; D, dopamine; GABA, gamma-aminobutyric acid; H, histamine; MAO, monoamine oxidase; NE, norepinephrine; NMDA, N-methyl-D-aspartate; SSNI, selective serotonin and norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor.